Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Alzheimer's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 184 articles:
HTML format



Single Articles


    November 2022
  1. HUANG J, Su B, Karhunen V, Gill D, et al
    Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization.
    Neurology. 2022 Nov 16. pii: WNL.0000000000201489.
    PubMed     Abstract available


  2. ROYALL DR
    Reader Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:918-919.
    PubMed    


  3. GANESH A, Galetta S
    Editors' Note: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:918.
    PubMed    


  4. QIU WQ, Tao Q, Akhter-Khan SC
    Author Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:919.
    PubMed    


  5. YU L, Hsieh YC, Pearse RV, Wang Y, et al
    Association of AK4 Protein From Stem Cell-Derived Neurons With Cognitive Reserve: An Autopsy Study.
    Neurology. 2022;99:e2264-e2274.
    PubMed     Abstract available


  6. ROSENBERG A, Ohlund-Wistbacka U, Hall A, Bonnard A, et al
    beta-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
    Neurology. 2022;99:e2102-e2113.
    PubMed     Abstract available


  7. TANGEN GG, Nilsson MH, Stomrud E, Palmqvist S, et al
    Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.
    Neurology. 2022;99:e2081-e2091.
    PubMed     Abstract available


  8. GHAHREMANI M, Wang M, Chen HY, Zetterberg H, et al
    Plasma P-Tau181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease.
    Neurology. 2022 Nov 2. pii: WNL.0000000000201517.
    PubMed     Abstract available


    October 2022
  9. PLANCHE V, Bouteloup V, Pellegrin I, Mangin JF, et al
    Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
    Neurology. 2022 Oct 19. pii: WNL.0000000000201479.
    PubMed     Abstract available


  10. GREENBERG BD, Pettigrew C, Soldan A, Wang J, et al
    CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4.
    Neurology. 2022;99:e1640-e1650.
    PubMed     Abstract available


    September 2022

  11. Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
    Neurology. 2022 Sep 30. pii: WNL.0000000000201298.
    PubMed    


  12. GALE SA, Heidebrink J, Grill J, Graff-Radford J, et al
    Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.
    Neurology. 2022 Sep 30. pii: WNL.0000000000201347.
    PubMed     Abstract available


  13. BEVERSDORF DQ, Scharre DW
    The Dilemma of the Clinical Utility of Alzheimer Biomarker Evaluation in Everyday Clinical Practice: My Favorite PETs.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201478.
    PubMed    


  14. DEMNITZ-KING H, Gonneaud J, Klimecki OM, Chocat A, et al
    Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults.
    Neurology. 2022;99:e1422-e1431.
    PubMed     Abstract available


  15. SUGDEN K, Caspi A, Elliott ML, Bourassa KJ, et al
    Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia.
    Neurology. 2022;99:e1402-e1413.
    PubMed     Abstract available


  16. CONSTANT AB, Basavaraju R, France J, Honig LS, et al
    Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology.
    Neurology. 2022 Sep 19. pii: WNL.0000000000200947.
    PubMed     Abstract available


  17. KAMAGATA K, Andica C, Takabayashi K, Saito Y, et al
    Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.
    Neurology. 2022 Sep 19. pii: WNL.0000000000201300.
    PubMed     Abstract available


  18. HICKS AJ, Ponsford JL, Spitz G, Dore V, et al
    beta-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study.
    Neurology. 2022;99:e1131-e1141.
    PubMed     Abstract available


  19. ZETTERBERG H, Schott JM
    Objectifying Subjective Cognitive Decline: The Prognostic Role of Alzheimer Biomarkers.
    Neurology. 2022 Sep 2. pii: WNL.0000000000201172.
    PubMed    


    August 2022
  20. QUILICO COUSINS KA, Arezoumandan S, Shellikeri S, Ohm D, et al
    CSF Biomarkers of Alzheimer Disease in Patients With Concomitant alpha-Synuclein Pathology.
    Neurology. 2022 Aug 30. pii: WNL.0000000000201202.
    PubMed     Abstract available


  21. DUBBELMAN MA, Verrijp M, Terwee CB, Jutten RJ, et al
    Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness.
    Neurology. 2022;99:e954-e964.
    PubMed     Abstract available


  22. JEONG SY, Suh CH, Shim WH, Lim JS, et al
    Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-amyloid Immunotherapy: A Meta-analysis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201019.
    PubMed     Abstract available


  23. SALMON DP, Smirnov DS, Coughlin DG, Hamilton JM, et al
    Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease.
    Neurology. 2022 Aug 26. pii: WNL.0000000000201068.
    PubMed     Abstract available


  24. ROSTAMZADEH A, Bohr L, Wagner M, Baethge C, et al
    Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-Analysis.
    Neurology. 2022 Aug 26. pii: WNL.0000000000201072.
    PubMed     Abstract available


  25. BILLETTE OV, Ziegler G, Aruci M, Schutze H, et al
    Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease.
    Neurology. 2022;99:e775-e788.
    PubMed     Abstract available


  26. JEONG SH, Cha J, Park M, Jung JH, et al
    Association of Enlarged Perivascular Spaces With Amyloid Burden and Cognitive Decline in Alzheimer Disease Continuum.
    Neurology. 2022 Aug 19. pii: WNL.0000000000200989.
    PubMed     Abstract available


  27. DUMURGIER J, Sabia S, Zetterberg H, Teunissen CE, et al
    A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
    Neurology. 2022;99:e669-e678.
    PubMed     Abstract available


  28. GILL D, Vujkovic M
    The Potential of Genetic Data for Prioritizing Drug Repurposing Efforts.
    Neurology. 2022;99:267-268.
    PubMed    


  29. CROTTY GF, Keavney JL, Alcalay RN, Marek K, et al
    Planning for Prevention of Parkinson Disease: Now Is the Time.
    Neurology. 2022;99.
    PubMed     Abstract available


  30. PIAZZA F, Caminiti SP, Zedde M, Presotto L, et al
    Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies.
    Neurology. 2022 Aug 8. pii: WNL.0000000000200892.
    PubMed     Abstract available


  31. AKINCI M, Pena-Gomez C, Operto G, Fuentes-Julian S, et al
    Pre-pandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200948.
    PubMed     Abstract available


  32. CEDRES N, Ferreira D, Nemy M, Machado A, et al
    Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200930.
    PubMed     Abstract available


    July 2022
  33. SHAHIM P, Zetterberg H, Simren J, Ashton NJ, et al
    Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes.
    Neurology. 2022;99:e347-e354.
    PubMed     Abstract available


  34. SCHINDLER SE, Karikari TK, Ashton NJ, Henson RL, et al
    Effect of Race on Prediction of Brain Amyloidosis by Plasma Abeta42/Abeta40, Phosphorylated Tau, and Neurofilament Light.
    Neurology. 2022;99:e245-e257.
    PubMed     Abstract available


  35. BORLAND E, Edgar C, Stomrud E, Cullen N, et al
    Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
    Neurology. 2022 Jul 14. pii: WNL.0000000000200817.
    PubMed     Abstract available


  36. WYNN M
    My First Patient With Alzheimer's.
    Neurology. 2022 Jul 14. pii: WNL.0000000000201087.
    PubMed    


  37. KEUSS SE, Coath W, Nicholas JM, Poole T, et al
    Associations of beta-Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort.
    Neurology. 2022;99:e129-e141.
    PubMed     Abstract available


    June 2022
  38. MONTINE TJ, Corrada MM, Kawas C, Bukhari S, et al
    Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old.
    Neurology. 2022 Jun 15. pii: WNL.0000000000200832.
    PubMed     Abstract available


  39. PETERSEN KK, Lipton RB, Grober E, Davatzikos C, et al
    Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data.
    Neurology. 2022;98:e2425-e2435.
    PubMed     Abstract available


  40. YANG JJ, Keohane LM, Pan X, Qu R, et al
    Association of Healthy Lifestyles with Risk of Alzheimer Disease and Related Dementias in Low-Income Black and White Americans.
    Neurology. 2022 Jun 13. pii: WNL.0000000000200774.
    PubMed     Abstract available


  41. TANG B, Wang Y, Jiang X, Thambisetty M, et al
    Genetic Variation in Targets of Anti-diabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.
    Neurology. 2022 Jun 2. pii: WNL.0000000000200771.
    PubMed     Abstract available


    May 2022
  42. KUMAR A, Janelidze S, Stomrud E, Palmqvist S, et al
    beta-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
    Neurology. 2022 May 31. pii: WNL.0000000000200605.
    PubMed     Abstract available


  43. DUMURGIER J, Sabia S, Zetterberg H, Teunissen C, et al
    Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
    Neurology. 2022 May 26. pii: WNL.0000000000200735.
    PubMed     Abstract available


  44. MOHANTY R, Ferreira D, Frerich S, Muehlboeck JS, et al
    Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
    Neurology. 2022 May 24. pii: WNL.0000000000200573.
    PubMed     Abstract available


  45. MCGIRR A, Nathan S, Ghahremani M, Gill S, et al
    Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms.
    Neurology. 2022;98:e2132-e2139.
    PubMed     Abstract available


  46. XICOTA L, Gyorgy B, Grenier-Boley B, Lecoeur A, et al
    Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults.
    Neurology. 2022 May 23. pii: WNL.0000000000200544.
    PubMed     Abstract available


  47. FARNSWORTH VON CEDERWALD B, Josefsson M, Wahlin A, Nyberg L, et al
    Association of Cardiovascular Risk Trajectory With Cognitive Decline and Incident Dementia.
    Neurology. 2022;98:e2013-e2022.
    PubMed     Abstract available


  48. LI Z, Heckman MG, Kanekiyo T, Martens YA, et al
    Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment.
    Neurology. 2022;98:e2036-e2045.
    PubMed     Abstract available


  49. ASKEN BM, Tanner JA, VandeVrede L, Mantyh WG, et al
    Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Neurology. 2022 May 16. pii: WNL.0000000000200678.
    PubMed     Abstract available


  50. AGOSTA F, Filippi M
    Natural Speech Analysis: A Window Into Alzheimer Disease Phenotypes.
    Neurology. 2022 May 4. pii: WNL.0000000000200843.
    PubMed    


  51. BEYDOUN MA, Beydoun HA, Fanelli-Kuczmarski MT, Weiss J, et al
    Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults.
    Neurology. 2022 May 4. pii: WNL.0000000000200289.
    PubMed     Abstract available


    April 2022
  52. CHO S, Quilico Cousins KA, Shellikeri S, Ash S, et al
    Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology.
    Neurology. 2022 Apr 29. pii: WNL.0000000000200581.
    PubMed     Abstract available


  53. WHITWELL J, Martin PR, Graff-Radford J, Machulda M, et al
    Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200336.
    PubMed     Abstract available


  54. VOGEL JW, Tosun D
    Multiple Cortical to Striatal Accumulation Trajectories of beta-Amyloid: Do All Roads Lead to Rome?
    Neurology. 2022;98:695-696.
    PubMed    


  55. COLLIJ LE, Salvado G, Wottschel V, Mastenbroek SE, et al
    Spatial-Temporal Patterns of beta-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis.
    Neurology. 2022;98:e1692-e1703.
    PubMed     Abstract available


  56. BEAUDIN AE, McCreary CR, Mazerolle EL, Gee M, et al
    Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy.
    Neurology. 2022;98:e1716-e1728.
    PubMed     Abstract available


  57. ARANHA MR, Fortea J, Carmona-Iragui M
    Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease.
    Neurology. 2022 Apr 25. pii: WNL.0000000000200704.
    PubMed    


  58. FRANK B, Ally M, Tripodis Y, Puzo C, et al
    Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease.
    Neurology. 2022 Apr 20. pii: WNL.0000000000200304.
    PubMed     Abstract available


  59. BEAMAN C, Kozii K, Hilal S, Liu M, et al
    Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration.
    Neurology. 2022;98:e1605-e1616.
    PubMed     Abstract available


  60. DIFRANCESCO JC, Stanzani L
    Increased Brain Volume: A Novel Biomarker of Neurodegeneration?
    Neurology. 2022;98:649-650.
    PubMed    


  61. SIBLE IJ, Nation DA
    Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200302.
    PubMed     Abstract available


  62. GRAFF-RADFORD J, Josephs K
    Author Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:644.
    PubMed    


  63. DASHEIFF R
    Reader Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:643.
    PubMed    


  64. SIEGLER JE 3RD, Galetta S
    Editors' Note: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:643.
    PubMed    


  65. FARRELL ME, Papp KV, Buckley RF, Jacobs HIL, et al
    Association of Emerging beta-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.
    Neurology. 2022;98:e1512-e1524.
    PubMed     Abstract available


  66. TIDEMAN P, Stomrud E, Leuzy A, Mattsson-Carlgren N, et al
    Association of beta-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
    Neurology. 2022;98:e1525-e1533.
    PubMed     Abstract available


  67. GAUTHREAUX KM, Teylan MA, Katsumata Y, Mock C, et al
    Limbic-Predominant Age-Related TDP-43 Encephalopathy: Medical and Pathologic Factors Associated With Comorbid Hippocampal Sclerosis.
    Neurology. 2022;98:e1422-e1433.
    PubMed     Abstract available


  68. GU Y, Kociolek A, Fernandez KK, Cosentino SA, et al
    Clinical Trajectories at the End of Life in Dementia Patients With Alzheimer Disease and Lewy Body Neuropathologic Changes.
    Neurology. 2022 Apr 4. pii: WNL.0000000000200259.
    PubMed     Abstract available


    March 2022
  69. GUAN Y, Ebrahimzadeh SA, Cheng CH, Chen W, et al
    Association of Diabetes and Hypertension With Brain Structural Integrity and Cognition in the Boston Puerto Rican Health Study Cohort.
    Neurology. 2022 Mar 30. pii: WNL.0000000000200120.
    PubMed     Abstract available


  70. ZAMMIT AR, Yu L, Petyuk V, Schneider JA, et al
    Cortical Proteins and Individual Differences in Cognitive Resilience in Older Adults.
    Neurology. 2022;98:e1304-e1314.
    PubMed     Abstract available


  71. SALINAS J, Beiser AS, Samra JK, O'Donnell A, et al
    Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline.
    Neurology. 2022;98:e1337-e1348.
    PubMed     Abstract available


  72. PETERSEN RC
    Detecting Alzheimer Disease Clinically: How Early Can We Go?
    Neurology. 2022 Mar 25. pii: WNL.0000000000200172.
    PubMed    


  73. VAN DE BEEK M, Ooms FAH, Ebenau JL, Barkhof F, et al
    Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
    Neurology. 2022;98:e1262-e1272.
    PubMed     Abstract available


  74. VAN LOENHOUD AC, Groot C, Bocancea DI, Barkhof F, et al
    Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200116.
    PubMed     Abstract available


  75. JOSEPHS KA, Weigand SD, Whitwell J
    Characterizing Amyloid Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200287.
    PubMed     Abstract available


  76. HESHMATOLLAH A, Fani L, Koudstaal PJ, Ghanbari M, et al
    Plasma Amyloid Beta, Total-Tau and Neurofilament Light Chain Levels and the Risk of Stroke: A Prospective Population-Based Study.
    Neurology. 2022 Mar 1. pii: WNL.0000000000200004.
    PubMed     Abstract available


    February 2022
  77. DAY GS, Scarmeas N, Dubinsky R, Coerver K, et al
    Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: Report of the AAN Guidelines Subcommittee.
    Neurology. 2022 Feb 23. pii: WNL.0000000000200176.
    PubMed     Abstract available


  78. GROBER E, Lipton RB, Sperling RA, Papp KV, et al
    Associations of Stages of Objective Memory Impairment (SOMI) with Amyloid PET and Structural MRI: The A4 Study.
    Neurology. 2022 Feb 23. pii: WNL.0000000000200046.
    PubMed     Abstract available


  79. MATTSSON-CARLGREN N, Grinberg LT, Boxer A, Ossenkoppele R, et al
    Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
    Neurology. 2022 Feb 16. pii: WNL.0000000000200040.
    PubMed     Abstract available


  80. CHU WT, Wang WE, Zaborszky L, Golde TE, et al
    Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract.
    Neurology. 2022;98:e700-e710.
    PubMed     Abstract available


  81. EBENAU JL, Pelkmans W, Verberk IMW, Verfaillie S, et al
    Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
    Neurology. 2022 Feb 2. pii: WNL.0000000000200035.
    PubMed     Abstract available


    January 2022
  82. BOWN CW, Carare RO, Schrag MS, Jefferson AL, et al
    Physiology and Clinical Relevance of Enlarged Perivascular Spaces in the Aging Brain.
    Neurology. 2022;98:107-117.
    PubMed     Abstract available


  83. WHITTINGTON MD, Campbell JD, Rind D, Fluetsch N, et al
    Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
    Neurology. 2022 Jan 12. pii: WNL.0000000000013314.
    PubMed     Abstract available


  84. BALLARINI T, Melo van Lent D, Wagner M
    Author Response: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:89-90.
    PubMed    


  85. GANESH A, Galetta S
    Editors' Note: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:88.
    PubMed    


  86. BRENNER SR
    Reader Response: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:88-89.
    PubMed    


  87. DA SILVA SOYOMBO NK, Rocha EL, Xavier LB, Oliveira RA, et al
    Biomarkers for Differential Diagnosis Between Chronic Traumatic Encephalopathy and Alzheimer Disease: A Systematic Review.
    Neurology. 2022;98.
    PubMed     Abstract available


    December 2021
  88. YOO HS, Jeon S, Cavedo E, Ko M, et al
    Association of beta-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.
    Neurology. 2021 Dec 30. pii: WNL.0000000000013277.
    PubMed     Abstract available


  89. CULLEN N, Janelidze S, Palmqvist S, Stomrud E, et al
    Association of CSF Abeta38 Levels With Risk of Alzheimer Disease-Related Decline.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013228.
    PubMed     Abstract available


  90. YU L, Boyle PA, Wingo AP, Yang J, et al
    Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013252.
    PubMed     Abstract available


  91. LI Y, Schindler SE, Bollinger JG, Ovod V, et al
    Validation of Plasma Amyloid-beta 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
    Neurology. 2021 Dec 14. pii: WNL.0000000000013211.
    PubMed     Abstract available


    November 2021
  92. SMIRNOV DS, Salmon DP, Galasko D, Goodwill VS, et al
    Association of Neurofibrillary Tangle Distribution With Age at Onset-Related Clinical Heterogeneity in Alzheimer Disease: An Autopsy Study.
    Neurology. 2021 Nov 22. pii: WNL.0000000000013107.
    PubMed     Abstract available


  93. ACOSTA LM
    I Wasn't There: Caring for a Patient With Trisomy 21, Alzheimer Disease, and Epilepsy Until His Final Days With COVID-19.
    Neurology. 2021 Nov 22. pii: WNL.0000000000013109.
    PubMed     Abstract available


  94. CHIONG W, Tolchin BD, Bonnie RJ, Busl K, et al
    Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement.
    Neurology. 2021 Nov 17. pii: WNL.0000000000013053.
    PubMed    


  95. KUSCHPEL MS
    Reader Response: Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Neurology. 2021;97:964-965.
    PubMed    


  96. SCHELBAUM E, Loughlin L, Jett S, Zang C, et al
    Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife.
    Neurology. 2021 Nov 3. pii: WNL.0000000000012941.
    PubMed     Abstract available


    October 2021
  97. LEUZY A, Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al
    Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
    Neurology. 2021;97:e1681-e1694.
    PubMed     Abstract available


    September 2021
  98. KIM YJ, Karceski S
    Alzheimer Disease and Mood.
    Neurology. 2021;97:e1363-e1366.
    PubMed    


  99. EDMONDS EC, Smirnov DS, Thomas KR, Graves LV, et al
    Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.
    Neurology. 2021;97:e1288-e1299.
    PubMed     Abstract available


  100. MILA-ALOMA M, Brinkmalm A, Ashton NJ, Kvartsberg H, et al
    CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012853.
    PubMed     Abstract available


  101. GARNIER-CRUSSARD A, Krolak-Salmon P
    Reader Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;97:608.
    PubMed    


  102. THERRIAULT J, Pascoal T, Gauthier S, Rosa-Neto P, et al
    Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;97:609.
    PubMed    


  103. JEONG SH, Kim HR, Kim J, Kim H, et al
    Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment.
    Neurology. 2021;97:e1110-e1122.
    PubMed     Abstract available


  104. HERSHEY LA, Tarawneh R
    Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
    Neurology. 2021;97:517-518.
    PubMed    


  105. SCHINDLER S, Li Y, Buckles VD, Gordon BA, et al
    Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012775.
    PubMed     Abstract available


  106. BUCIUC M, Josephs KA, Jones DT, Whitwell JL, et al
    Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012783.
    PubMed    


  107. MCCARTER S, Lesnick TG, Lowe V, Mielke MM, et al
    Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-beta PET Signal.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012770.
    PubMed     Abstract available


    August 2021
  108. FRISON E, Proust-Lima C, Mangin JF, Habert MO, et al
    Diabetes Mellitus and Cognition: Pathway Analysis in the MEMENTO Cohort.
    Neurology. 2021;97:e836-e848.
    PubMed     Abstract available


  109. SANDERS AE
    A Century-Old Problem: Cognition and Neuropsychiatric Symptoms in Alzheimer Disease.
    Neurology. 2021 Aug 20. pii: WNL.0000000000012616.
    PubMed    


  110. EIKELBOOM WS, van den Berg E, Singleton EH, Baart SJ, et al
    Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations.
    Neurology. 2021 Aug 19. pii: WNL.0000000000012598.
    PubMed     Abstract available


  111. LI J
    Alzheimer's Villanelle.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012612.
    PubMed    


  112. PETERSEN RC
    Mild Cognitive Impairment Criteria in Alzheimer's Disease Neuroimaging Initiative: Meeting Biological Expectations.
    Neurology. 2021 Aug 2. pii: WNL.0000000000012588.
    PubMed    


    July 2021
  113. TAO Q, Alvin Ang TF, Akhter-Khan SC, Itchapurapu IS, et al
    Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous Apolipoprotein E varepsilon4 Carriers.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012512.
    PubMed     Abstract available


  114. BOCANCEA DI, Catharina van Loenhoud A, Groot C, Barkhof F, et al
    Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012499.
    PubMed     Abstract available


  115. GROTHE MJ, Moscoso A, Ashton NJ, Karikari TK, et al
    Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012513.
    PubMed     Abstract available


  116. POGGESI A
    Resilience and Resistance in Aging and Alzheimer Disease: Another Step to Fill the Gap Between Clinicians and Researchers.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012500.
    PubMed    


  117. WILSON RS, Wang T, Yu L, Grodstein F, et al
    Cognitive Activity and Onset Age of Incident Alzheimer Disease Dementia.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012388.
    PubMed     Abstract available


  118. SALLOWAY S, Cummings J
    Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease.
    Neurology. 2021 Jul 7. pii: WNL.0000000000012451.
    PubMed    


    June 2021
  119. BUCIUC M, Duffy JR, Machulda MM, Graff-Radford J, et al
    Clinical, Imaging, and Pathologic Characteristics of Patients With Right Versus Left Hemisphere-Predominant Logopenic Progressive Aphasia.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012322.
    PubMed     Abstract available


  120. JUTTEN RJ, Sikkes SAM, Van der Flier WM, Scheltens P, et al
    Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.
    Neurology. 2021;96:e2673-e2684.
    PubMed     Abstract available


  121. BUCKLEY RF, Knopman DS
    Cognitive Heterogeneity in Alzheimer Clinical Trials: Harnessing Noise to Achieve Meaningfulness.
    Neurology. 2021;96:1017-1018.
    PubMed    


    May 2021
  122. HUGHES TM, Hajjar I
    Is Late-onset Alzheimer Disease Spelled "ATV(N)"?
    Neurology. 2021 May 24. pii: WNL.0000000000012259.
    PubMed    


  123. DONADIO V, Wang Z, Incensi A, Rizzo G, et al
    In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
    Neurology. 2021;96:e2513-e2524.
    PubMed     Abstract available


  124. FRIEDMAN LG, McKeehan N, Hara Y, Cummings JL, et al
    Value-Generating Exploratory Trials in Neurodegenerative Dementias.
    Neurology. 2021;96:944-954.
    PubMed     Abstract available


  125. MAYBLYUM DV, Becker JA, Jacobs HIL, Buckley RF, et al
    Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.
    Neurology. 2021 May 5. pii: WNL.0000000000012108.
    PubMed     Abstract available


  126. BALLARINI T, Melo van Lent D, Brunner J, Schroder A, et al
    Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age.
    Neurology. 2021 May 5. pii: WNL.0000000000012067.
    PubMed     Abstract available


  127. BELLAVER B, Ferrari-Souza JP, Uglione da Ros L, Carter SF, et al
    Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021 May 5. pii: WNL.0000000000012109.
    PubMed     Abstract available


  128. HAZRATI LN, Schwab N
    Embracing the Unknown in the Diagnosis of Traumatic Encephalopathy Syndrome.
    Neurology. 2021;96:835-836.
    PubMed    


    April 2021
  129. BOERWINKLE AH, Wisch JK, Chen CD, Gordon BA, et al
    Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012123.
    PubMed     Abstract available


  130. KARCESKI S
    The Effects of Long-term Medication Use in Alzheimer Disease.
    Neurology. 2021;96:e2247-e2250.
    PubMed    


  131. XU H, Garcia-Ptacek S, Jonsson L, Wimo A, et al
    Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Neurology. 2021;96:e2220-e2230.
    PubMed     Abstract available


  132. ROBERTS G, Durcan Mrcpi R, Donaghy PC, Lawley S, et al
    Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012060.
    PubMed     Abstract available


  133. HAMILTON CA, Matthews FE, Donaghy PC, Taylor JP, et al
    Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease.
    Neurology. 2021 Apr 19. pii: WNL.0000000000012024.
    PubMed     Abstract available


  134. HOWARD E, Irwin DJ, Rascovsky K, Nevler N, et al
    Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
    Neurology. 2021;96:e1855-e1864.
    PubMed     Abstract available


    March 2021
  135. QIAN J, Betensky RA, Hyman BT, Serrano-Pozo A, et al
    Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.
    Neurology. 2021 Mar 26. pii: WNL.0000000000011883.
    PubMed     Abstract available


  136. GOTTESMAN RF, Hamilton R
    Recruiting Diverse Populations in Clinical Trials: How Do We Overcome Selection Bias?
    Neurology. 2021;96:509-510.
    PubMed    


  137. KANG SH, Kim ME, Jang H, Kwon H, et al
    Amyloid Positivity in Alzheimer/Subcortical-Vascular Spectrum.
    Neurology. 2021 Mar 15. pii: WNL.0000000000011833.
    PubMed     Abstract available


  138. SMIRNOV DS, Galasko D, Hiniker A, Edland S, et al
    Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease.
    Neurology. 2021 Mar 15. pii: WNL.0000000000011772.
    PubMed     Abstract available


  139. BARKHOF BF, Pressman PS
    Time Is of the Essence: Early Detection of Incipient Alzheimer Pathology.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011739.
    PubMed    


    February 2021
  140. ROBINSON-PAPP J, Saylor D
    HIV in the Brain: From Devastating Dementia to White Matter Hyperintensities.
    Neurology. 2021 Feb 26. pii: WNL.0000000000011735.
    PubMed    


  141. HUYNH K, Piguet O, Kwok J, Dobson-Stone C, et al
    Clinical and Biological Correlates of White Matter Hyperintensities in Patients with Behavioral-variant Frontotemporal Dementia and Alzheimer Disease.
    Neurology. 2021 Feb 17. pii: WNL.0000000000011638.
    PubMed     Abstract available


  142. THERRIAULT J, Pascoal TA, Benedet AL, Tissot C, et al
    Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;96:e975-e985.
    PubMed     Abstract available


  143. RENTZ DM, Papp KV, Mayblyum DV, Sanchez JS, et al
    Association of Digital Clock Drawing with PET Amyloid and Tau Pathology in Normal Older Adults.
    Neurology. 2021 Feb 15. pii: WNL.0000000000011697.
    PubMed     Abstract available


  144. DETERS K, Napolioni V, Sperling RA, Greicius MD, et al
    Amyloid PET imaging in self-identified non-Hispanic Blacks from the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
    Neurology. 2021 Feb 10. pii: WNL.0000000000011599.
    PubMed     Abstract available


  145. FERREIRA D, Nordberg A, Westman E
    Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:238.
    PubMed    


  146. ULEMAN JF, Melis RJF, Olde Rikkert MGM
    Reader Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:237-238.
    PubMed    


  147. GANESH A, Galetta S
    Editors' Note: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:237.
    PubMed    


    January 2021
  148. JOSEPH-MATHURIN N, Wang G, Kantarci K, Jack CR Jr, et al
    Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease.
    Neurology. 2021 Jan 25. pii: WNL.0000000000011542.
    PubMed     Abstract available


  149. SAJJADI SA, Ash S, Cappa S
    Glass half full: Preservation of memory in Alzheimer-related primary progressive aphasia.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011404.
    PubMed    


  150. MESULAM MM, Coventry C, Kuang A, Bigio EH, et al
    Memory resilience in Alzheimer's disease with primary progressive aphasia.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011397.
    PubMed     Abstract available


  151. BLAZHENETS G, Frings L, Ma Y, Sorensen A, et al
    Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011521.
    PubMed     Abstract available


  152. JAGUST WJ, Landau SM
    Temporal Dynamics of Beta-amyloid Accumulation in Aging and Alzheimer's Disease.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011524.
    PubMed     Abstract available


  153. TRELLE AN, Carr VA, Wilson EN, Swarovski MS, et al
    Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011477.
    PubMed     Abstract available


  154. THERRIAULT J, Pascoal TA, Savard M, Benedet AL, et al
    Topographic Distribution of Amyloid-beta, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease.
    Neurology. 2021;96:e81-e92.
    PubMed     Abstract available


    December 2020
  155. KNOPMAN DS, Jagust WJ
    Alzheimer Disease Spectrum: Syndrome and Etiology from Clinical and PET Imaging Perspectives.
    Neurology. 2020 Dec 22. pii: WNL.0000000000011415.
    PubMed    


  156. KOYAMA AK, Irwin DJ
    Alzheimer disease biomarker profiles in dementia with Lewy bodies: Does A plus T spell D-L-B?
    Neurology. 2020;95:1076-1077.
    PubMed    


  157. GICAS KM, Honer WG, Wilson RS, Boyle PA, et al
    Association of serial position scores on memory tests and hippocampal-related neuropathologic outcomes.
    Neurology. 2020;95:e3303-e3312.
    PubMed     Abstract available


  158. PETTIGREW C, Soldan A, Wang J, Wang MC, et al
    Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline.
    Neurology. 2020;95:e3093-e3103.
    PubMed     Abstract available


  159. PALMQVIST S, Eshaghi A
    Spatial distribution of tau and beta-amyloid pathologies and their role in different Alzheimer's disease phenotypes.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011272.
    PubMed    


  160. LA JOIE R, Visani AV, Lesman-Segev OH, Baker SL, et al
    Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011270.
    PubMed     Abstract available


    November 2020
  161. KARCESKI S
    How a buildup of abnormal proteins in the brain may be the key to understanding Alzheimer disease.
    Neurology. 2020;95:e2951-e2953.
    PubMed    


  162. YOUNAN D, Wang X, Casanova R, Barnard R, et al
    PM2.5 associated with gray matter atrophy reflecting increased Alzheimers risk in older women.
    Neurology. 2020 Nov 18. pii: WNL.0000000000011149.
    PubMed     Abstract available


  163. ILLAN-GALA I, Lleo A, Karydas A, Staffaroni AM, et al
    Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease.
    Neurology. 2020 Nov 16. pii: WNL.0000000000011226.
    PubMed     Abstract available


  164. GRAFF-RADFORD J, Knopman D, Jones D
    Author response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:846.
    PubMed    


  165. ALLALI G, Laticevschi T
    Reader response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:845-846.
    PubMed    


  166. SIEGLER JE 3RD, Galetta S
    Editors' note: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:845.
    PubMed    


    October 2020
  167. KIM HR, Lee T, Choi JK, Jeong Y, et al
    Genetic variants beyond amyloid and tau associated with cognitive decline: A cohort study.
    Neurology. 2020;95:e2366-e2377.
    PubMed     Abstract available


  168. WEIGAND AJ, Bondi MW, Thomas KR, Campbell NL, et al
    Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.
    Neurology. 2020;95:e2295-e2304.
    PubMed     Abstract available


  169. KERCHNER GA, Filippi M
    Abeta-PET pathology accumulation index: Ready for the clinic?
    Neurology. 2020 Oct 19. pii: WNL.0000000000011060.
    PubMed    


  170. LEUZY A, Lilja J, Buckley CJ, Ossenkoppele R, et al
    Derivation and utility of an Abeta-PET pathology accumulation index to estimate Abeta load.
    Neurology. 2020 Oct 19. pii: WNL.0000000000011031.
    PubMed     Abstract available


  171. BENNETT DA, Knopman DS
    Extending Alzheimer disease biomarker studies into the Hispanic community.
    Neurology. 2020;95:665-666.
    PubMed    


  172. NAG S, Barnes LL, Yu L, Wilson RS, et al
    Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents.
    Neurology. 2020;95:e2056-e2064.
    PubMed     Abstract available


  173. GERTJE EC, van Westen D, Panizo C, Mattsson-Carlgren N, et al
    Association of enlarged perivascular spaces and measures of small vessel and Alzheimers disease.
    Neurology. 2020 Oct 12. pii: WNL.0000000000011046.
    PubMed    


  174. KAPASI A, Yu L, Boyle PA, Barnes LL, et al
    Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging.
    Neurology. 2020;95:e1951-e1962.
    PubMed     Abstract available


  175. CATRICALA E, Polito C, Presotto L, Esposito V, et al
    Neural correlates of naming errors across different neurodegenerative diseases: A FDG-PET study.
    Neurology. 2020 Oct 1. pii: WNL.0000000000010967.
    PubMed     Abstract available


    September 2020
  176. HANES J, Kovac A, Kvartsberg H, Kontsekova E, et al
    Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias.
    Neurology. 2020 Sep 24. pii: WNL.0000000000010814.
    PubMed     Abstract available


  177. BRENOWITZ WD, Besser LM, Kukull WA, Keene CD, et al
    Clinician-judged hearing impairment and associations with neuropathologic burden.
    Neurology. 2020;95:e1640-e1649.
    PubMed     Abstract available


  178. SCHREIBER S, DiFrancesco JC
    Impaired occipital cerebrovascular reactivity as a biomarker for vascular beta-amyloid.
    Neurology. 2020;95:415-416.
    PubMed    


  179. GUZMAN-VELEZ E, Martinez J, Papp K, Baena A, et al
    Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.
    Neurology. 2020;95:e1312-e1321.
    PubMed     Abstract available


    August 2020
  180. KIM JW, Byun MS, Lee JH, Yi D, et al
    Serum albumin and beta-amyloid deposition in the human brain.
    Neurology. 2020;95:e815-e826.
    PubMed     Abstract available


  181. VAN DER ZANDE JJ, Gouw AA, van Steenoven I, van de Beek M, et al
    Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies.
    Neurology. 2020;95:e662-e670.
    PubMed     Abstract available


    July 2020
  182. COLLIJ LE, Heeman F, Salvado G, Ingala S, et al
    Multi-tracer model for staging cortical amyloid deposition using PET imaging.
    Neurology. 2020 Jul 16. pii: WNL.0000000000010256.
    PubMed     Abstract available


  183. EBENAU JL, Timmers T, Wesselman LMP, Verberk IMW, et al
    ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
    Neurology. 2020;95:e46-e58.
    PubMed     Abstract available


  184. SAKAE N, Santos OA, Pedraza O, Litvan I, et al
    Clinical and pathologic features of cognitive-predominant corticobasal degeneration.
    Neurology. 2020;95:e35-e45.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: